Impact of mass drug administration for elimination of lymphatic filariasis in Nepal.
Identifieur interne : 000101 ( PubMed/Corpus ); précédent : 000100; suivant : 000102Impact of mass drug administration for elimination of lymphatic filariasis in Nepal.
Auteurs : Chet Raj Ojha ; Basant Joshi ; Khagendra Prakash Kc ; Shyam Prakash Dumre ; Keshav Kumar Yogi ; Bandana Bhatta ; Tulasi Adhikari ; Kathryn Crowley ; Babu Ram MarasiniSource :
- PLoS neglected tropical diseases [ 1935-2735 ] ; 2017.
English descriptors
- KwdEn :
- Albendazole (administration & dosage), Child, Diethylcarbamazine (administration & dosage), Disease Transmission, Infectious (prevention & control), Drug Therapy (methods), Drug Utilization, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (prevention & control), Elephantiasis, Filarial (transmission), Female, Filaricides (administration & dosage), Health Services Research, Humans, Male, Nepal (epidemiology), Surveys and Questionnaires, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Albendazole, Diethylcarbamazine, Filaricides.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial, Nepal.
- methods : Drug Therapy.
- prevention & control : Disease Transmission, Infectious, Elephantiasis, Filarial.
- transmission : Elephantiasis, Filarial.
- Child, Drug Utilization, Female, Health Services Research, Humans, Male, Surveys and Questionnaires, Treatment Outcome.
Abstract
Lymphatic filariasis (LF) is a neglected tropical disease transmitted by mosquitoes. Nepal has implemented a national effort to eliminate LF by 2020 through mass drug administration (MDA) using diethylcarbamazine (DEC) and albendazole (ALB). We assessed the impact of MDAs on LF in selected districts of Nepal after the recommended six MDA rounds had been completed.
DOI: 10.1371/journal.pntd.0005788
PubMed: 28723904
Links to Exploration step
pubmed:28723904Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of mass drug administration for elimination of lymphatic filariasis in Nepal.</title><author><name sortKey="Ojha, Chet Raj" sort="Ojha, Chet Raj" uniqKey="Ojha C" first="Chet Raj" last="Ojha">Chet Raj Ojha</name><affiliation><nlm:affiliation>Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Joshi, Basant" sort="Joshi, Basant" uniqKey="Joshi B" first="Basant" last="Joshi">Basant Joshi</name><affiliation><nlm:affiliation>Leadership for Environment and Development Nepal, Kathmandu, Nepal.</nlm:affiliation></affiliation></author><author><name sortKey="Kc, Khagendra Prakash" sort="Kc, Khagendra Prakash" uniqKey="Kc K" first="Khagendra Prakash" last="Kc">Khagendra Prakash Kc</name><affiliation><nlm:affiliation>Leadership for Environment and Development Nepal, Kathmandu, Nepal.</nlm:affiliation></affiliation></author><author><name sortKey="Dumre, Shyam Prakash" sort="Dumre, Shyam Prakash" uniqKey="Dumre S" first="Shyam Prakash" last="Dumre">Shyam Prakash Dumre</name><affiliation><nlm:affiliation>Department of Immunogenetics, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Yogi, Keshav Kumar" sort="Yogi, Keshav Kumar" uniqKey="Yogi K" first="Keshav Kumar" last="Yogi">Keshav Kumar Yogi</name><affiliation><nlm:affiliation>World Health Organization, Lalitpur, Nepal.</nlm:affiliation></affiliation></author><author><name sortKey="Bhatta, Bandana" sort="Bhatta, Bandana" uniqKey="Bhatta B" first="Bandana" last="Bhatta">Bandana Bhatta</name><affiliation><nlm:affiliation>Save the Children International, Kathmandu, Nepal.</nlm:affiliation></affiliation></author><author><name sortKey="Adhikari, Tulasi" sort="Adhikari, Tulasi" uniqKey="Adhikari T" first="Tulasi" last="Adhikari">Tulasi Adhikari</name><affiliation><nlm:affiliation>Epidemiology and Disease Control Division, Ministry of Health and Population, Government of Nepal, Kathmandu, Nepal.</nlm:affiliation></affiliation></author><author><name sortKey="Crowley, Kathryn" sort="Crowley, Kathryn" uniqKey="Crowley K" first="Kathryn" last="Crowley">Kathryn Crowley</name><affiliation><nlm:affiliation>RTI International, Washington, District of Columbia, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Marasini, Babu Ram" sort="Marasini, Babu Ram" uniqKey="Marasini B" first="Babu Ram" last="Marasini">Babu Ram Marasini</name><affiliation><nlm:affiliation>Epidemiology and Disease Control Division, Ministry of Health and Population, Government of Nepal, Kathmandu, Nepal.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28723904</idno><idno type="pmid">28723904</idno><idno type="doi">10.1371/journal.pntd.0005788</idno><idno type="wicri:Area/PubMed/Corpus">000101</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000101</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of mass drug administration for elimination of lymphatic filariasis in Nepal.</title><author><name sortKey="Ojha, Chet Raj" sort="Ojha, Chet Raj" uniqKey="Ojha C" first="Chet Raj" last="Ojha">Chet Raj Ojha</name><affiliation><nlm:affiliation>Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Joshi, Basant" sort="Joshi, Basant" uniqKey="Joshi B" first="Basant" last="Joshi">Basant Joshi</name><affiliation><nlm:affiliation>Leadership for Environment and Development Nepal, Kathmandu, Nepal.</nlm:affiliation></affiliation></author><author><name sortKey="Kc, Khagendra Prakash" sort="Kc, Khagendra Prakash" uniqKey="Kc K" first="Khagendra Prakash" last="Kc">Khagendra Prakash Kc</name><affiliation><nlm:affiliation>Leadership for Environment and Development Nepal, Kathmandu, Nepal.</nlm:affiliation></affiliation></author><author><name sortKey="Dumre, Shyam Prakash" sort="Dumre, Shyam Prakash" uniqKey="Dumre S" first="Shyam Prakash" last="Dumre">Shyam Prakash Dumre</name><affiliation><nlm:affiliation>Department of Immunogenetics, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Yogi, Keshav Kumar" sort="Yogi, Keshav Kumar" uniqKey="Yogi K" first="Keshav Kumar" last="Yogi">Keshav Kumar Yogi</name><affiliation><nlm:affiliation>World Health Organization, Lalitpur, Nepal.</nlm:affiliation></affiliation></author><author><name sortKey="Bhatta, Bandana" sort="Bhatta, Bandana" uniqKey="Bhatta B" first="Bandana" last="Bhatta">Bandana Bhatta</name><affiliation><nlm:affiliation>Save the Children International, Kathmandu, Nepal.</nlm:affiliation></affiliation></author><author><name sortKey="Adhikari, Tulasi" sort="Adhikari, Tulasi" uniqKey="Adhikari T" first="Tulasi" last="Adhikari">Tulasi Adhikari</name><affiliation><nlm:affiliation>Epidemiology and Disease Control Division, Ministry of Health and Population, Government of Nepal, Kathmandu, Nepal.</nlm:affiliation></affiliation></author><author><name sortKey="Crowley, Kathryn" sort="Crowley, Kathryn" uniqKey="Crowley K" first="Kathryn" last="Crowley">Kathryn Crowley</name><affiliation><nlm:affiliation>RTI International, Washington, District of Columbia, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Marasini, Babu Ram" sort="Marasini, Babu Ram" uniqKey="Marasini B" first="Babu Ram" last="Marasini">Babu Ram Marasini</name><affiliation><nlm:affiliation>Epidemiology and Disease Control Division, Ministry of Health and Population, Government of Nepal, Kathmandu, Nepal.</nlm:affiliation></affiliation></author></analytic><series><title level="j">PLoS neglected tropical diseases</title><idno type="eISSN">1935-2735</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (administration & dosage)</term><term>Child</term><term>Diethylcarbamazine (administration & dosage)</term><term>Disease Transmission, Infectious (prevention & control)</term><term>Drug Therapy (methods)</term><term>Drug Utilization</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Elephantiasis, Filarial (transmission)</term><term>Female</term><term>Filaricides (administration & dosage)</term><term>Health Services Research</term><term>Humans</term><term>Male</term><term>Nepal (epidemiology)</term><term>Surveys and Questionnaires</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Nepal</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Transmission, Infectious</term><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child</term><term>Drug Utilization</term><term>Female</term><term>Health Services Research</term><term>Humans</term><term>Male</term><term>Surveys and Questionnaires</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lymphatic filariasis (LF) is a neglected tropical disease transmitted by mosquitoes. Nepal has implemented a national effort to eliminate LF by 2020 through mass drug administration (MDA) using diethylcarbamazine (DEC) and albendazole (ALB). We assessed the impact of MDAs on LF in selected districts of Nepal after the recommended six MDA rounds had been completed.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28723904</PMID><DateCreated><Year>2017</Year><Month>07</Month><Day>20</Day></DateCreated><DateCompleted><Year>2017</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>Impact of mass drug administration for elimination of lymphatic filariasis in Nepal.</ArticleTitle><Pagination><MedlinePgn>e0005788</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0005788</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lymphatic filariasis (LF) is a neglected tropical disease transmitted by mosquitoes. Nepal has implemented a national effort to eliminate LF by 2020 through mass drug administration (MDA) using diethylcarbamazine (DEC) and albendazole (ALB). We assessed the impact of MDAs on LF in selected districts of Nepal after the recommended six MDA rounds had been completed.</AbstractText><AbstractText Label="METHODOLOGY AND PRINCIPAL FINDINGS" NlmCategory="RESULTS">Baseline surveys were conducted in seven districts and mapping data were used as baseline in the other three districts before starting MDA in 2009. LF antigen (Ag) prevalence ranged from 1.06% to 20% among districts included in the baseline and mapping study. The number of people who received DEC and ALB were recorded during each MDA round and population-based cluster surveys were conducted at least once in each district during the life of the program. The reported MDA coverage in five districts was consistently at least 65%. Two districts achieved the targeted coverage in four out of five rounds and the rest three districts achieved the target only in the first round. A pre-transmission assessment survey (pre-TAS) was conducted in one sentinel site and at least one spot check site in each of the districts after five MDA rounds. In pre-TAS, all the sites of five districts (Pyuthan, Arghakhanchi, Kaski, Bhaktapur, and Kathmandu) and all but one spot check site of Lalitpur district had LF Ag < 2% (ranging from 0.0% to 1.99%). Transmission assessment survey (TAS) was conducted in six evaluation units (EUs) consisting of six districts qualified on pre-TAS. Though MDA coverage of 65% was not achieved in three districts (Kathmandu, Lalitpur and Bhaktapur), Nepal government in consultation with World Health Organization (WHO) decided to conduct TAS. All six EUs achieved the LF Ag threshold required to stop MDA in TAS, despite the low reported MDA coverage in those three districts.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although Nepal has achieved significant progress towards LF elimination, five rounds of MDA were not sufficient to disrupt the transmission cycle in all districts, probably because of high baseline prevalence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ojha</LastName><ForeName>Chet Raj</ForeName><Initials>CR</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-6816-8892</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Basant</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Leadership for Environment and Development Nepal, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kc</LastName><ForeName>Khagendra Prakash</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Leadership for Environment and Development Nepal, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumre</LastName><ForeName>Shyam Prakash</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Immunogenetics, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yogi</LastName><ForeName>Keshav Kumar</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>World Health Organization, Lalitpur, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatta</LastName><ForeName>Bandana</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Save the Children International, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adhikari</LastName><ForeName>Tulasi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Epidemiology and Disease Control Division, Ministry of Health and Population, Government of Nepal, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowley</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>RTI International, Washington, District of Columbia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marasini</LastName><ForeName>Babu Ram</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Epidemiology and Disease Control Division, Ministry of Health and Population, Government of Nepal, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical><Chemical><RegistryNumber>F4216019LN</RegistryNumber><NameOfSubstance UI="D015766">Albendazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2010 Mar 23;4(3):e640</RefSource><PMID Version="1">20351776</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 1993 Feb;48(2):178-85</RefSource><PMID Version="1">8447520</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int Health. 2011 Mar;3(1):22-6</RefSource><PMID Version="1">24038047</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nepal Health Res Counc. 2014 May-Aug;12 (27):124-9</RefSource><PMID Version="1">25726571</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2013 Dec 05;7(12):e2584</RefSource><PMID Version="1">24340120</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasit Vectors. 2014 Jul 01;7:300</RefSource><PMID Version="1">24984769</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2012;6(11):e1926</RefSource><PMID Version="1">23209865</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2014 Jul 31;8(7):e3035</RefSource><PMID Version="1">25078276</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitol Res. 2013 Jan;112(1):35-44</RefSource><PMID Version="1">23239094</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitology. 1993;107 Suppl:S147-58</RefSource><PMID Version="1">8115179</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 1991 Jan;44(1):3-10</RefSource><PMID Version="1">1996738</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 2007 Dec;77(6):1069-73</RefSource><PMID Version="1">18165524</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004171</RefSource><PMID Version="1">26496129</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2014 Nov 13;8(11):e3281</RefSource><PMID Version="1">25393404</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Filaria J. 2003 Mar 19;2(1):7</RefSource><PMID Version="1">12694630</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2014 Sep;108(9):538-49</RefSource><PMID Version="1">24728444</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Trop Med Parasitol. 2004 Oct;98(7):703-14</RefSource><PMID Version="1">15509424</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bull World Health Organ. 1997;75(6):491-503</RefSource><PMID Version="1">9509621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Community Health. 2015 Feb;40(1):34-40</RefSource><PMID Version="1">24996654</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Vector Borne Dis. 2010 Mar;47(1):61-4</RefSource><PMID Version="1">20231778</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasit Vectors. 2008 May 27;1(1):14</RefSource><PMID Version="1">18505577</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Health Popul Nutr. 2013 Jun;31(2):171-7</RefSource><PMID Version="1">23930334</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2008 Oct 08;2(10):e317</RefSource><PMID Version="1">18841205</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2008;2(12):e344</RefSource><PMID Version="1">19065257</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lymphat Res Biol. 2013 Sep;11(3):144-8</RefSource><PMID Version="1">24044755</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018562" MajorTopicYN="N">Disease Transmission, Infectious</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004358" MajorTopicYN="N">Drug Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006302" MajorTopicYN="N">Health Services Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009390" MajorTopicYN="N">Nepal</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>08</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>07</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28723904</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0005788</ArticleId><ArticleId IdType="pii">PNTD-D-16-01403</ArticleId><ArticleId IdType="pmc">PMC5536438</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000101 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000101 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28723904
|texte= Impact of mass drug administration for elimination of lymphatic filariasis in Nepal.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28723904" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |